Skip to content


Adapsyn’s platform analyses metabolomic and genomic data to identify, isolate, and assay novel drug-like small molecules from bacteria.

Genomic Analysis

Our genomic analysis toolkit prioritizes bacteria for downstream interrogation by identifying gene clusters that encode novel molecules. We can determine the type of molecule encoded, generate structure predictions for the molecule, as well as evaluate its potential to be developed as a therapeutic. We can also identify gene clusters that encode small molecules that target specific enzymes.
Once the parameters for a development program have been established, we can generate a list of candidate bacterial strains for metabolomic interrogation. Adapsyn’s technology is unparalleled in its ability to provide a comprehensive genomic evaluation of bacterial biosynthetic potential.

Metabolomic Pipeline

Our metabolomic pipeline identifies all novel molecules in a given extract sample using high-throughput high-resolution LCMS, predicts additional chemical characteristics of those molecules, and use an automated workflow to isolate molecules that meet a development program’s parameters. Once isolated, candidate molecules can be assayed for bioactivity to identify hits for downstream development.
This can be done both on material from a pre-existing extract library or from material collected from new fermentations. Our in-house fermentation workflow utilizes high-throughput culturing to define media conditions that optimize natural target molecule production for scale-up, without the need for heterologous gene expression. Strain selection to hit molecule isolation and assay can be completed in approximately six weeks.